Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03993353
Title Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of California, San Diego
Indications

head and neck squamous cell carcinoma

Therapies

Pembrolizumab + Tadalafil

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.